A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Phase 3 Recruiting
614 enrolled
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/2 Recruiting
90 enrolled
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
Phase 1/2 Recruiting
45 enrolled
LAP100
Phase 3 Recruiting
356 enrolled
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Phase 2 Recruiting
50 enrolled
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Phase 3 Recruiting
94 enrolled
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Phase 1/2 Recruiting
56 enrolled
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
Phase NA Recruiting
49 enrolled
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Phase 2 Recruiting
36 enrolled
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2 Recruiting
224 enrolled
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
Phase 1/2 Recruiting
48 enrolled
Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Phase 2 Recruiting
30 enrolled
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Phase 2 Recruiting
100 enrolled
Folfox+Irinotecan+Chemort In Esophageal Cancer
Phase 2 Recruiting
40 enrolled
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2 Recruiting
208 enrolled
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Phase NA Recruiting
39 enrolled
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Phase 2 Recruiting
135 enrolled
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
Phase 1 Recruiting
59 enrolled
PIPAC-NAL-IRI
Phase 1 Recruiting
45 enrolled
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Phase 2 Recruiting
29 enrolled
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
Phase 2 Recruiting
51 enrolled
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.
Phase NA Recruiting
68 enrolled
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
Phase 2 Recruiting
60 enrolled
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
Phase 2 Recruiting
30 enrolled
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
Phase 1/2 Recruiting
138 enrolled
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Phase 2 Recruiting
56 enrolled
LIAES
Phase 2 Recruiting
30 enrolled
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Phase 2 Recruiting
120 enrolled
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Phase 2 Recruiting
78 enrolled
Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
Phase 2 Recruiting
36 enrolled
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
Phase 2 Recruiting
173 enrolled
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
Phase 2 Recruiting
86 enrolled
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
Phase 2 Recruiting
87 enrolled
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
Phase 2 Recruiting
40 enrolled
NALIRIFOX as Induction Therapy in LAPC
Phase 2 Recruiting
20 enrolled
Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan
Recruiting
933 enrolled
NaliCap
Phase 2 Recruiting
200 enrolled
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Phase NA Recruiting
53 enrolled
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Phase 1 Recruiting
78 enrolled